Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia

키워드

참고문헌 (48)

1. Leucht C, "Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials", Schizophr Res, 127, pp.83~92 (2011)
2. Tiihonen J, "Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia", JAMA Psychiatry, 74, pp.686~693 (2017)
3. Kim HO, "Real-world effectiveness of longacting injections for reducing recurrent hospitalizations in patients with schizophrenia", Ann Gen Psychiatry, 19, pp.1~ (2020)
4. Dasom Lee, "Effects of Paliperidone Palmitate on Healthcare Utilization and Costs for Patients with Schizophrenia: A Claim-based Mirror-image Study in South Korea", Clinical Psychopharmacology and Neuroscience, 18(2), pp.303~310 (2020), 대한정신약물학회[DOI]
5. Kishimoto T, "Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia : a meta-analysis of prospective and retrospective cohort studies", Schizophr Bull, 44, pp.603~619 (2018)
6. Pae CU, "Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia : systematic review and indirect treatment comparison", Int Clin Psychopharmacol, 32, pp.235~248 (2017)
7. Miller BJ, "Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil : a 6-month, prospective, open-label study", Schizophr Res, 208, pp.44~48 (2019)
8. Kim SW, "Editorial : Early intervention in psychotic disorders", Front Psychiatry, 11, pp.574532~ (2020)
9. Tiihonen J, "A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia", Am J Psychiatry, 168, pp.603~609 (2011)
10. Kim B, "Long-acting injectable antipsychotics for first-episode schizophrenia : the pros and cons", Schizophr Res Treatment, 2012, pp.560836~ (2012)
11. Stevens GL, "Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia", Early Interv Psychiatry, 10, pp.365~377 (2016)
12. Abdel-Baki A, "Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder", Early Interv Psychiatry, 14, pp.69~79 (2020)
13. Shin W, "Clinical effectiveness of early treatment with paliperidone palmitate in schizophrenia : A retrospective real-world study in South Korea", Early Interv Psychiatry (2021)[DOI]
14. Giordano G, "Aripiprazole long-acting injection during first episode schizophrenia-an exploratory analysis", Front Psychiatry, 10, pp.935~ (2020)
15. Kane JM, "Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia : a randomized clinical trial", JAMA Psychiatry, 77, pp.1217~1224 (2020)
16. Kay SR, "The positive and negative syndrome scale(PANSS)for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
17. 이중서, "한국판 양성 및 음성증후군 척도(Positive and Negative Syndrome Scale)의 신뢰도와 타당도", 신경정신의학, 40(6), pp.1090~1105 (2001), 대한신경정신의학회
18. Morosini PL, "Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale(SOFAS)to assess routine social functioning", Acta Psychiatr Scand, 101, pp.323~329 (2000)
19. 이정구, "한국판 Personal and Social Performance 척도 (K-PSP)의 표준화 연구", 대한정신약물학회지, 17(6), pp.497~506 (2006), 대한정신약물학회
20. Simpson GM, "A rating scale for extrapyramidal side effects", Acta Psychiatr Scand Suppl, 212, pp.11~19 (1970)
21. Barnes TR, "A rating scale for drug-induced akathisia", Br J Psychiatry, 154, pp.672~676 (1989)
22. Guy W, "ECDEU assessment manual for psychopharmacology", US Department of Health, Education, and Welfare, 534~537 (1976)
23. Naber D, "Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs", Schizophr Res, 50, pp.79~88 (2001)
24. 김성완, "단축형 항정신병약물치료 중 주관적 안녕감 척도의 표준화 연구", 대한정신약물학회지, 18(4), pp.221~230 (2007), 대한정신약물학회
25. Lee SJ, "Development of an emotional awareness test consisting of problem solving tasks", Korean J Soc Pers Psychol, 15, pp.65~86 (2001)
26. Guy W, "Handbook of psychiatric measures", pp.100~102 (2000), American Psychiatric Association
27. McGorry PD, "The recognition and optimal management of early psychosis : an evidence-based reform", World Psychiatry, 1, pp.76~83 (2002)
28. Mustafa S, "Real-life assessment of aripiprazole monthly(Abilify Maintena)in schizophrenia : a Canadian naturalistic non-interventional prospective cohort study", BMC Psychiatry, 19, pp.114~ (2019)
29. Lieberman JA, "The NIMH-CATIE Schizophrenia Study : what did we learn?", Am J Psychiatry, 168, pp.770~775 (2011)
30. Kern RS, "The neurocognitive effects of aripiprazole:an open-label comparison with olanzapine", Psychopharmacology(Berl), 187, pp.312~320 (2006)
31. Kim SW, "Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia", Clin Neuropharmacol, 32, pp.243~249 (2009)
32. Naber D, "Qualify : a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia", Schizophr Res, 168, pp.498~504 (2015)
33. Kim SW, "Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia", Clin Neuropharmacol, 33, pp.121~125 (2010)
34. 고유경, "The Prevalence of Metabolic Syndrome in Schizophrenic Patients Using Antipsychotics", Clinical Psychopharmacology and Neuroscience, 11(2), pp.80~88 (2013), 대한정신약물학회
35. Sung-Wan Kim, "Physical Health Literacy and Health-related Behaviors in Patients with Psychosis", Clinical Psychopharmacology and Neuroscience, 17(2), pp.279~287 (2019), 대한정신약물학회[DOI]
36. Sugawara N, "Prevalence of metabolic syndrome among patients with schizophrenia in Japan", Schizophr Res, 123, pp.244~250 (2010)
37. Pillinger T, "Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology : a systematic review and network meta-analysis", Lancet Psychiatry, 7, pp.64~77 (2020)
38. Vázquez-Bourgon J, "A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone : a pragmatic clinical trial in first episode psychosis patients", Eur Neuropsychopharmacol, 39, pp.46~55 (2020)
39. Kim SW, "Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia", Hum Psychopharmacol, 24, pp.565~573 (2009)
40. Hiroyuki Kamei, "Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia", Clinical Psychopharmacology and Neuroscience, 18(1), pp.49~57 (2020), 대한정신약물학회[DOI]
41. Kim SW, "The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 38, pp.228~235 (2012)
42. Naber D, "Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study", Schizophr Res, 192, pp.205~210 (2018)
43. Chi-Un Pae, "Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study", Clinical Psychopharmacology and Neuroscience, 19(2), pp.233~242 (2021), 대한정신약물학회[DOI]
44. Rossi A, "Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone", Int Clin Psychopharmacol, 23, pp.216~222 (2008)
45. Seunghyong Ryu, "Network Structures of Social Functioning Domains in Schizophrenia and Bipolar Disorder: A Preliminary Study", Clinical Psychopharmacology and Neuroscience, 18(4), pp.571~579 (2020), 대한정신약물학회[DOI]
46. Kampman O, "Indicators of medication compliance in first-episode psychosis", Psychiatry Res, 110, pp.39~48 (2002)
47. Lambert M, "Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia", Acta Psychiatr Scand, 118, pp.220~229 (2008)
48. Kim SW, "Comparison of attitudes toward long-acting injectable antipsychotics among psychiatrists and patients", Int Clin Psychopharmacol, 28, pp.80~86 (2013)

관련 논문AI추천